Latest filings (excl ownership)
424B5
Prospectus supplement for primary offering
3 May 24
EFFECT
Notice of effectiveness
1 May 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
8-K
Entry into a Material Definitive Agreement
4 Apr 24
10-K
2023 FY
Annual report
13 Mar 24
8-K
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update
13 Mar 24
S-8
Registration of securities for employees
12 Feb 24
S-3
Shelf registration
12 Feb 24
8-K
80 patients now enrolled in PRECISION1 supporting two-thirds interim analysis expected in 3Q 2024
14 Dec 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K/A
Aadi Bioscience Reports Financial Results for the Third Quarter 2023 and Provides Corporate Update
8 Nov 23
8-K
Results of Operations and Financial Condition
8 Nov 23
8-K
Aadi Bioscience Appoints Dave Lennon, Ph.D. as President and Chief Executive Officer
2 Oct 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
8-K
Aadi Bioscience Announces Financial Results for the Second Quarter 2023 and Provides
9 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
16 Jun 23
10-Q
2023 Q1
Quarterly report
10 May 23
8-K
Aadi Bioscience Announces Financial Results and Operational Update for the First Quarter 2023 and Provides Update on PRECISION 1 Tumor Agnostic Trial
10 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
S-8
Registration of securities for employees
29 Mar 23
10-K
2022 FY
Annual report
28 Mar 23
8-K/A
Departure of Directors or Certain Officers
28 Mar 23
8-K
Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Corporate Update
28 Mar 23
8-K
Aadi Bioscience Announces Leadership Transition
3 Mar 23
8-K
Entry into a Material Definitive Agreement
23 Jan 23
8-K
Amendments to Articles of Incorporation or Bylaws
7 Dec 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
25 Nov 22
10-Q
2022 Q3
Quarterly report
9 Nov 22
8-K
Aadi Bioscience Announces Financial Results for the Third Quarter of 2022 and Provides Corporate Update
9 Nov 22
EFFECT
Notice of effectiveness
7 Nov 22
424B3
Prospectus supplement
4 Nov 22
CORRESP
Correspondence with SEC
2 Nov 22
UPLOAD
Letter from SEC
1 Nov 22
S-3
Shelf registration
26 Oct 22
D
$72.50 mm in equity / options, sold $72.50 mm, 13 investors
11 Oct 22
8-K
Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing
22 Sep 22
Latest ownership filings
4
Neil Desai
1 May 24
3
BRYAN BALL
26 Apr 24
4
Neil Desai
3 Apr 24
4
Neil Desai
4 Mar 24
4
LORETTTA M ITRI
4 Mar 24
4
David James Lennon
4 Mar 24
4
Scott M. Giacobello
4 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
4
Neil Desai
2 Feb 24
4
Neil Desai
2 Jan 24
4
Neil Desai
7 Dec 23
4
Neil Desai
5 Dec 23
144
Notice of proposed sale of securities
1 Dec 23
4
Neil Desai
2 Nov 23
4
Neil Desai
3 Oct 23
4
David James Lennon
3 Oct 23
3
David James Lennon
3 Oct 23
4
Neil Desai
6 Sep 23
144
Notice of proposed sale of securities
1 Sep 23
4
Neil Desai
3 Aug 23
4
Neil Desai
6 Jul 23
144
Notice of proposed sale of securities
3 Jul 23
4
Behzad Aghazadeh
20 Jun 23
4
Karin M. Hehenberger
20 Jun 23
4
Richard E Maroun
20 Jun 23
4
Anupam Dalal
20 Jun 23
4
Emma Reeve
20 Jun 23
4
Caley Castelein
20 Jun 23
4
Neil Desai
6 Jun 23
4
Neil Desai
5 Jun 23
4
Neil Desai
5 May 23
4
Neil Desai
3 May 23
4
Neil Desai
6 Apr 23
4
Neil Desai
5 Apr 23
4
Scott M. Giacobello
4 Apr 23
144
Notice of proposed sale of securities
3 Apr 23
4
Mohammad Hirmand
29 Mar 23
3
Mohammad Hirmand
29 Mar 23
4
LORETTTA M ITRI
2 Mar 23
4
Scott M. Giacobello
2 Mar 23